Design of New Topoisomerase II Inhibitors Based upon a Quinobenzoxazine Self-Assembly Model
Authors:
- 1 October 1998
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 41 (22) , 4273-4278
Abstract
A new class of pyridobenzophenoxazine compounds has been developed as topoisomerase II inhibitors for anticancer chemotherapy. These compounds were designed based on a proposed model of a quinobenzoxazine self-assembly complex on DNA. They showed excellent inhibitory effects on several tumor cell lines with nanomolar IC50 values. Their cytotoxic potency correlates with their ability to unwind DNA and inhibit topoisomerase II.Keywords
This publication has 4 references indexed in Scilit:
- Quinobenoxazines: A Class of Novel Antitumor Quinolones and Potent Mammalian DNA Topoisomerase II Catalytic InhibitorsBiochemistry, 1994
- A single point mutation in the DNA gyrase A protein greatly reduces binding of fluoroquinolones to the gyrase-DNA complexAntimicrobial Agents and Chemotherapy, 1993
- Mechanism of DNA cleavage and substrate recognition by a bovine apurinic endonucleaseBiochemistry, 1989
- Decatenation of kinetoplast DNA by topoisomerases.Journal of Biological Chemistry, 1980